Six CAR-T-cell therapies have been approved by the European Commission and the US FDA, and other T-cell therapies are being ...

A groundbreaking study has identified circulating cell-free DNA as a potential biomarker for predicting early relapse in ...

GCC-4001 is a cell therapy commercialized by Artiva Biotherapeutics, with a leading Phase II program in B-Cell Non-Hodgkin Lymphoma.

Discover how the emerging field of using CAR-T cell therapy to treat lupus could offer a potential cure for the autoimmune ...

T-cell therapy is a type of cancer immunotherapy where patients' T-cells are collected and genetically modified to produce ...

So far, the only program to reach clinical development is KYV-101, a CAR T-cell therapy derived from a patient's T cells (i.e ...

别称： B-lymphocyte antigen CD19, Cluster of Differentiation 19, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3 概述： 悉得（Syd Labs）提供重组小鼠 IgG1 同 ...

A key target for these therapies is a protein called CD19 found on the cancer cells,” added Dr ... YTHDF2 promotes ATP ...

Nektar Therapeutics (NKTR) announced results of its Phase 2 proof-of-concept study, which evaluated NKTR-255 as an adjuvant treatment ...

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed ...